View in EDS HTML Full Text PDF Full Text

Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.

Saved in:
Bibliographic Details
Title: Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma.
Authors: Beck M; Department of Nuclear Medicine, University Hospital of Erlangen, Friedrich-Alexander-Universität- Erlangen Nürnberg, Erlangen, Germany. michael.beck@uk-erlangen.de.; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany. michael.beck@uk-erlangen.de., Blumenberg V; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bücklein VL; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany., Bundschuh RA; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Nuclear Medicine, Faculty of Medicine, University Hospital of Augsburg, Augsburg, Germany.; Department of Nuclear Medicine, University Hospital Carl Gustav Carus at the TU Dresden, Dresden, Germany., Harrer DC; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital of Regensburg, Regensburg, Germany., Hirschbühl K; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany., Jung J; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany., Kunz WG; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Menhart K; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany., Winkelmann M; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Yakushev I; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Munich, Germany., Illert AL; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany., Eckstein M; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Pathology, University Hospital of Erlangen, Friedrich-Alexander-Universität- Erlangen Nürnberg, Erlangen, Germany., Völkl S; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität-Erlangen Nürnberg, Erlangen, Germany., Claus R; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.; Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany., Hansmann L; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital of Regensburg, Regensburg, Germany., Hecker JS; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.; Center for Translational Cancer Research, Technical University of Munich (TUM), TranslaTUM, Munich, Germany., Kuwert T; Department of Nuclear Medicine, University Hospital of Erlangen, Friedrich-Alexander-Universität- Erlangen Nürnberg, Erlangen, Germany.; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany., Mackensen A; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität-Erlangen Nürnberg, Erlangen, Germany., Subklewe M; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany., Hellwig D; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany.; Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany., Müller F; Bavarian Cancer Research Center, Resp. Site (Augsburg, LMU Munich, TUM Munich, Erlangen, Regensburg), Germany. fabian.mueller@uk-erlangen.de.; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität-Erlangen Nürnberg, Erlangen, Germany. fabian.mueller@uk-erlangen.de.
Source: EJNMMI research [EJNMMI Res] 2025 Mar 17; Vol. 15 (1), pp. 25. Date of Electronic Publication: 2025 Mar 17.
Publication Type: Journal Article
Journal Info: Publisher: Springer Berlin Country of Publication: Germany NLM ID: 101560946 Publication Model: Electronic Cited Medium: Print ISSN: 2191-219X (Print) Linking ISSN: 2191219X NLM ISO Abbreviation: EJNMMI Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2191-219X
DOI:10.1186/s13550-025-01201-1